360773-84-8

Basic information

• Product Name: t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate
• Synonyms: 1-(N-BOC-Amino)-1-(4-bromophenyl)cyclopropane;t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate;tert-Butyl (1-(4-broMophenyl)cyclopropyl)carbaMate;[1-(4-Bromo-phenyl)-cyclopropyl]-carbamic acid tert-butyl ester;tert-Butyl N-[1-(4-bromophenyl)cyclopropyl]carbamate;tert-Butyl (1-(4-bromophenyl);Carbamic acid, N-[1-(4-bromophenyl)cyclopropyl]-, 1,1-dimethylethyl ester
• CAS NO: 360773-84-8
• Molecular Formula: C₁₄H₁₈BrNO₂
• Molecular Weight: 312.20222
• Mol File: 360773-84-8.mol

Chemical Properties

• Boiling Point: 385.2±31.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: 11.94±0.20(Predicted)
• CAS DataBase Reference: t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate(360773-84-8)
• EPA Substance Registry System: t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate(360773-84-8)

Safety Data

• Hazardous Substances Data: 360773-84-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate is used as a reagent in organic synthesis for the preparation of various chemical compounds. Its unique structure and reactivity allow for the formation of new chemical entities with potential applications in different industries.
Used in Pharmaceutical Research:
t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate is used as a potential pharmaceutical intermediate in the development of new drugs. Its structural features and reactivity make it a valuable building block for the synthesis of bioactive molecules with therapeutic potential.
Used in Pharmaceutical Industry:
t-Butyl 1-(4-bromophenyl)cyclopropylcarbamate is used as a key intermediate in the synthesis of pharmaceuticals. Its unique structural features and reactivity contribute to the development of novel drugs with improved efficacy and safety profiles.

Upstream product

• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 345965-54-0 1-(4-bromophenyl)-cyclopropylamine 
• 133017-10-4 Butyl 2-(4-bromophenyl)acetate 
• 952289-92-8 1-(4-bromophenyl)cyclopropan-1-amine hydrochloride 

Downstream Products

• 952289-92-8 1-(4-bromophenyl)cyclopropan-1-amine hydrochloride 
• 345965-54-0 1-(4-bromophenyl)-cyclopropylamine 
• 630384-19-9 tert-butyl (1-(4-iodophenyl)cyclopropyl)carbamate 
• 1313441-88-1 tert-butyl N-[1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]carbamate 
• 1374261-40-1 1-[4-(2-phenyl-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-3-yl)phenyl]cyclopropanamine 
• 1374263-34-9 tert-butyl {1-[4-(2-phenyl-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-3-yl]phenyl}cyclopropyl}carbamate 
• 1014645-87-4 methyl 4-(1-aminocyclopropyl)benzoate hydrochloride 
• 1380750-61-7 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid 
• 1380750-73-1 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid 
• 1380753-67-2 methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate 
• 1380750-84-4 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid 
• 1380750-88-8 4-(1-(5-chloro-2-(3-((3-fluorophenyl)(methoxyimino)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid 
• 1380754-55-1 methyl 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate 
• 1380755-18-9 methyl 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate 

Relevant articles and documents

NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Synthesis method of (4-(1-((tert-butoxycarbonyl)amino)cyclopropyl)phenyl)borate

The invention discloses a synthesis method of (4-(1-((tert-butoxycarbonyl)amino)cyclopropyl)phenyl)borate. The preparation method comprises the following steps: S1, dissolving a compound A with a massof 1.5-200 g and a volume of 5-900 mmol in 20-2000 mL o

General and cost-effective synthesis of 1-heteroaryl/arylcycloalkylamines and their broad applications

A general and cost-effective route has been developed to synthesize 1-heteroarylsubstituted cycloalkylamines from readily available heteroarylacetate in good yields. This synthesis features a LHMDS promoted cyclization and one-pot hydrolysis/Curtius rearr

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE

The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as

PHARMACEUTICALLY ACTIVE COMPOUNDS

The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.

PHENOXYETHYL PIPERIDINE COMPOUNDS

The present invention provides a compound of the Formula II: Formula II wherein X is: R1 is H, -CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined toge

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.